Loading
Life sciences · Journal article
Ibnosina Journal of Medicine and Biomedical Sciences · October 12, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Abstract Gout is closely linked to metabolic disorders such as obesity, diabetes, and chronic kidney disease. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and sodium-glucose cotransporter 2 inhibitors (SGLT2i) may provide additional benefits beyond standard urate-lowering therapy (ULT). A comparative historical cohort study was conducted among adult patients with gout comparing ULT alone versus in combination with GLP-1 RAs or SGLT2i for at least 6 months. Clinical and laboratory data were analyzed over a 2-year follow-up. A total of 64 adult patients with gout with a median disease duration of 6.7 years were included. The mean age was 55.6 years (range 27–92) with a majority being male (45, 70.3%) patients. The mean number of gout flares decreased from 1.44 flares/year prior to ULT to 0.78 flares/year after therapy initiation (p < 0.001). Half of the subjects (32 patients) received either GLP-1 RA or SGLT2i agents (intervention group) while the other half were considered as controls. Both groups had similar age and sex distributions and received standard ULT with febuxostat or allopurinol. The intervention group had a lower number of flares: 0.32 per year compared to 1.22 in the control group (mean difference −0.9; 95% confidence interval −1.4 to −0.38; p < 0.001). In multivariate analysis, the antidiabetic agents were independent predictors of reduced flare frequency, after controlling for other covariates. Adjunctive treatment with SGLT2i or GLP-1 RAs was associated with fewer gout flares over 24 months in this real-world historical cohort. These findings should be interpreted cautiously and warrant confirmation in prospective controlled studies.